Pancreatic cancer is the fourth most common cause of cancer-related death in the Western world.
About the group
Mechanisms that underlie treatment resistance, such as tumour heterogeneity, tumour-stroma interactions, and metabolic rewiring are investigated on human tumour tissues and in primary human cell cultures.
The research group is part of the Norwegian Cancer Society´s National Group of Expertise on Pancreatic Cancer.
- Morphological (intra-)tumour heterogeneity and its correlation with structural and functional diversity in pancreatic cancer.
Funded by The Norwegian Cancer Society.
- Characterisation of residual cancer following neoadjuvant therapy for pancreatic cancer.
Funded by Helse Sør-Øst.
- Ex vivo culturing of precision-cut human pancreatic cancer slices.
- Metabolic rewiring and chemoresistance in pancreatic cancer.
Funded by Helse Sør-Øst, Family Blix Endowment, and Fondsstiftelsen at Oslo University Hospital.
- Implementation of imaging mass cytometry and automated whole-slideanalyses of colorectal and pancreatic cancer.
Funded by Fondsstiftelsen at Oslo University Hospital.